any reason, the earlier and later observations were registered separately. Likewise, if a patient had coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty, observations made before and after those procedures were registered separately, If there were any changes in the prescription of one or more of the antiplatelet agents, lipid-lowering agents, ACEI, -blockers, warfarin, calcium antagonists, nitrates or antiarrhythmic agents, observations made before and after administration of the new medications were registered separately.
Follow-up Examination
Serial blood tests, exercise ECGs, and echocardiography were carried out several times for hospitalized patients and approximately twice a year for outpatients. Left ventricular wall motion abnormality was evaluated using echocardiography according to Heger et al. 6 QRS scores on ECGs were calculated as an index related to infarct size according to Wagner et al. 7 Hyperlipidemia was considered to be present if the patient had a past history of total cholesterol >220 mg/dl and a history of hypertension was defined as casual systolic blood pressure >160 mmHg or diastolic pressure >95 mmHg. Obesity was considered to be present if patients had a body mass index >25.
Exclusion and Lost-to-Follow
Because the present study focused on the long-term prognoses of patients with healed MI, cardiac events occurring within 7 days of onset of symptoms were excluded. If a patient ceased visiting the hospital, efforts were made to contact him/her by telephone and determine the reason so as to avoid overlooking cardiac or other medical events. Those patients who stopped coming in for unknown reasons and whom we failed to contact were defined as lost-tofollow.
Primary End-Points
The primary end-points were cardiac events, which included fatal and nonfatal recurrent MI, sudden death and death by congestive heart failure. 1986-1987 1988-1990 1991-1993 1994-1996 1997-1999 
Statistical Analysis
Data are presented as means ± one standard deviation. For categoric data, the Mantel-Haenszel chi-square test was used as the measure of trends. 3 Differences between 2 values were tested using the 2 test. Two-sided probability values are presented; values of p<0.05 were considered significant.
Results

Study Population
During the 14-year study period, a total of 6,602 post-MI patients (5,320 males, 1,282 females; mean age, 58.9±10.4 years at onset) were registered. The mean time from onset of symptoms to registry was 34.4±42.5 months, and the mean observation period was 12.6±16.3 months. Patients were grouped in 5 time periods as shown in Table 1 . Peak serum creatine kinase activity after the first MI was higher among patients enrolled during 1997-1999, and more of those patients were treated with coronary thrombolysis, percutaneous transluminal coronary angioplasty and coronary artery bypass graft surgery than in earlier periods. Among patients with multivessel disease, 4.2% had bypass surgery in 1986-1987; this increased to 10.2% in 1988-1990, 13.5% in 1991-1993, 24 .0% in 1994-1996 and 28.2% in 1997-1999. The incidence of wall motion abnormalities and QRS scores on ECGs declined over the course of the study period, as did the incidence of angina pectoris.
Coronary Risk Factors
During 1986-1987, 386 patients reported a history of hypertension; their mean blood pressure was 138±23 /80±14 mmHg. During 1997-1999, 625 patients reported a history of hypertension; in this group, the mean blood pressure was 130±18/75±11 mmHg, whereas in those with no history of it was 122±17/70±11 mmHg. Among the former group of patients, both systolic and diastolic blood pressures were significantly (p<0.01) lower in 1997-1999 than in 1986-1987. The percentage of smokers, including exsmokers, remained high throughout the study period. There were 232 diabetic patients enrolled during 1986-1987 and 384 during 1997-1999. Hemoglobin A1c (8.3±2.9 vs 6.8±1.1: p<0.01) and total cholesterol (218±46 vs 199±36 mg/dl: p<0.01) were both significantly lower in 1997-1999 than in 1986-1987. On the other hand, the incidence of obesity trended upward, nearly doubling over the course of the study period.
Laboratory Findings
Laboratory findings showed no remarkable changes over the course of the study period, though total cholesterol trended downward. During 1986-1987, 465 patients reported a history of hyperlipidemia: the mean total cholesterol was 236±41 mg/dl and 14.0% were taking statins. In 1997-1999, by contrast, 653 patients reported a history of hyperlipidemia: total cholesterol was 211±35 mg/dl (p< 0.01 vs 1986-1987), and 89.5% were on statins.
Trends in Drug Treatment
Drug treatment showed a marked shift toward antiplatelet agents over the course of the study period, with 51.5% of patients receiving antiplatelet agents in 1986-1987 vs 83.4% in 1997-1999. During 1986-1987 aspirin alone was taken by only 2.0% of patients, but aspirin combined with other antiplatelet agents was taken by 48.1% of patients. During 1997-1999, however, 49.8% of patients took aspirin alone, and combined use had declined to 39.5%. The use of warfarin also reduced during this period. Prescription of lipid-lowering agents increased over the years from 29.8% to 52.6%, with 80.5% of those prescribed during 1997-1999 being statins. Use of ACEI also increased, and -blockers were used consistently in more than half of post-MI patients (53.4-64.5%), and among the 1,854 patients who were 65 years or older at onset, 1,005 (54.2%) were prescribed - 1986-1987 1988-1990 1991-1993 1994-1996 1997-1999 blockers. Use of calcium antagonists trended downward, as did that of nitrates, though they were still taken by 41.0% and 45.7% of patients, respectively, during 1997-1999. Antiarrhythmic agents were used in a limited number of patients. (Table 2 , Fig 1) Among the 6,602 post-MI patients, 195 cardiac events were recorded over the course of the study period (3.0%, 28.1 events/1,000 person · year). There was no statistical difference between the number of cardiac events occurring in males and females: 159 cardiac events (3.0%, 27.6 events /1,000 person year) among the 5,320 male patients and 36 events (2.8%, 30.3 events/1,000 person· year) among the 1,282 female patients. There were 78 cardiac deaths (1.2%, 11.2 events/1,000 person · year) and 147 recurrent MIs (2.2%, 21.2 events/1,000 person · year). There was a downward trend in the incidence of post-MI cardiac events throughout the study period, with the number of cardiac events declining from 44.9 events/1,000 person year in 1986-1987 to 22.5 events/1,000 person · year in 1997-1999 (p<0.01).
Trends in Cardiac Events
Discussion
Recent Decline in Cardiac Events in Post-MI Patients
According to the Framingham Study published in 1993, 8 following a first MI, there were 68.4 coronary deaths and 39 recurrent MIs per 1,000 person · year among males and 110.6 coronary deaths and 42.2 recurrent MIs per 1,000 person · year among females during a 34-year follow-up from 1948 to 1981 (no gender difference). This was substantially higher than the 11.2 cardiac deaths and 21.2 recurrent MIs per 1000 person · year observed during the 14-year period evaluated in the present study and is likely the result in part to differences in race and community. In addition, the Framingham Study was initiated and ended many years before the present study, suggesting that improved health habits and better treatment modalities also contributed to the observed improvement in the long-term prognosis of post-MI patients.
Successful Use of Reperfusion Therapies
The risk factors that affect clinical outcome following acute MI are multifactorial, so it is difficult to identify any single factor contributing to the improvement in the outcome for post-MI patients shown in the present study. Nevertheless, one would expect limitation of infarct size by myocardial salvage and preservation of left ventricular function to be major determinants affecting patient prognosis. For instance, in 1986-1987 only 27.8% of patients received coronary thrombolysis at the onset of symptoms; this increased to 45.6% by 1997-1999. In Japan, we used urokinase as a thrombolytic agent in 1985; tissue-type plasminogen activator (tPA), which gave a higher rate of reperfusion was adopted in 1991, and then in 1998 mutant tPA became available. Reduction of wall motion abnormalities and QRS scores on the ECG may reflect the successful use of such reperfusion therapy during the acute phase. There has also recently been a tremendous increase in the number of patients receiving percutaneous transluminal coronary angioplasty or coronary artery bypass graft surgery. In particular, bypass surgery in cases of multivessel disease may have contributed much to the improved long-term prognosis. With the use of such interventional therapy, the incidence of post-MI angina pectoris has been reduced by more than half. However, only 28.2% of patients with multivessel disease in the present study population received bypass surgery and we would encourage greater use of this technique.
Effective Secondary Prevention of MI
Accumulating evidence is clarifying which drugs are effective for secondary prevention of MI and which are not. 9, 10 In that regard, randomized clinical trials have had a measurable influence on the patterns of medical practice. For example, in 1994 the Antiplatelet Trialists Collaboration concluded that with respect to every category of highrisk patient, antiplatelet therapy was definitely protective. 11 In addition, Stafford reported that aspirin use among outpatients with coronary artery disease in the United States increased from 5.0% of patients in 1980 to 26.6% in 1996. 12 In the present study population, aspirin was used more in 1997-1999, possibly encouraged by the results, which showed aspirin (50 mg/day) plus either dipyridamole (150 mg/day) or ticlopidine (200 mg/day) was effective in preventing recurrent MI 13 Based on convincing evidence that lowering serum lipid is effective at preventing cardiac events, 14 52.6% of patients were taking lipid-lowering agents (mostly statins) by 1997-1999. ACEI are effective in patients following MI, particularly those with the signs and symptoms of heart failure or with chronic left ventricular dysfunction. 9 Consistent with those findings, we also found that increased use of ACEI likely contributes to improved long-term prognosis. The important role ofblockers for secondary prevention of MI has been pointed out repeatedly, 15, 16 but their use is limited, especially among elderly patients. 17 Use of -blockers in our study population was high compared with that described by Heller et al, who reported that the use of -blockers among elderly survivors of acute MI (>65 years of age) increased from 39.6% in 1994 to 58.6% in 1997. 18 Based in part on the recent evidence indicating the efficacy of -blockers in preventing cardiac events, 19 their use at our institution is relatively high, even among elderly patients, and still higher (71-72%) usage of -blockers in post-MI patients has been reported in Finland and Sweden. 20 Warfarin is effective for prevention of thrombotic events in some patients, and antiarrhythmic agents were used in a selected group within the study population.
Despite the availability of new types of calcium antagonists, 21 their use has been declining, possibly because of reports that indicated them to be ineffective at preventing secondary MI. 22, 23 In addition, GISSI-3 24 and ISIS-4 25 have both shown that long-term use of nitrates does not reduce mortality in post-MI patients; indeed studies from Japan 26, 27 indicate long-term use of nitrates may even be deleterious. Although, we found a slight decline in the use of nitrates since 1986, 45.7% of patients were still taking nitrates in 1997-1999. Among elderly survivors of acute MI, 74.8-76.5% are reportedly taking nitrates and other vasodilators, 18 and Rogers et al found that approximately 30% of patients are discharged with nitrates. 3 A randomized trial to evaluate long-term nitrate use in coronary artery disease would thus seem warranted.
Coronary Risk Factors
Approximately half the present patients had high serum total cholesterol or a history of hyperlipidemia. Mean total cholesterol declined from approximately 214 mg/dl in 1986-1987 to 199 mg/dl in 1997-1999, perhaps thanks to the increased use of statins. Blood pressure control is important to improve long-term prognosis in post-MI patients. 28 Blood pressure was also lower in hypertensive patients in 1997-1999 than in 1986-1987, and among diabetic patients, hemoglobin A1c as well as total cholesterol was markedly lower during the same period. These positive findings among outpatients would be expected to have also contributed to the improved long-term prognosis. However, it was surprising how many post-MI patients have a history of smoking or are presently smokers, and there has been an increase the incidence of obesity among our patients. Perhaps additional patient education for reducing these coronary risk factors may further improve the long-term prognosis of post-MI patients.
Study Limitation
The results of the present study are drawn from post-MI patients at a single institution, and thus may not represent the national trend in Japan. To reach a national consensus on the proper advice for medical doctors and their patients, observations from many institutions in many districts will be needed.
Conclusion
There has been a marked decline in the incidence of cardiac events in post-MI patients during the 14 years of the study. The implementation of the findings of recent clinical trials and more use of therapies known to reduce cardiac events have contributed much to the improvement in long-term prognosis of these patients.
